Methods of treating age related disorders

Abstract

The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enhancing the cognitive function of a patient in need thereof. Such methods may include administering a therapeutically effective amount of a MetAP2 inhibitor.

What is claimed is: 
     
         1 . A method of treating an age-related neuromuscular disorder in a patient in need thereof, comprising administering to the patient an effective amount of an irreversible MetAP2 inhibitor that covalently binds to MetAP2, wherein said inhibitor, upon administration increases the level of metabolic products formed in the citric acid cycle and does not substantially increase alphaketoglutarate in the liver of said patient. 
     
     
         2 . The method of  claim 1 , wherein said patient exhibits a reduction in expression of mCLK1. 
     
     
         3 . The method of  claim 1 , wherein the patient, upon administration of the MetAP2 inhibitor, exhibits a decrease in non-mitochondrial oxidative damage. 
     
     
         4 . The method of  claim 1 , wherein the patient, upon administration of the MetAP2 inhibitor, exhibits increased mitochondrial oxidative stress. 
     
     
         5 . The method of  claim 1 , wherein said therapeutically effective amount does not substantially modulate or suppress angiogenesis. 
     
     
         6 . The method of  claim 1 , further comprising administration of the MetAP2 inhibitor until a marker level is returned to a normal range. 
     
     
         7 . The method of  claim 6 , wherein the marker is C-reactive protein. 
     
     
         8 . The method of  claim 1 , wherein said MetAP2 inhibitor is administered parenterally or non-parenterally. 
     
     
         9 . The method of  claim 1 , wherein the MetAP2 inhibitor is a fumagillin analog. 
     
     
         10 . The method of  claim 9 , wherein the MetAP2 inhibitor is administered at a dose of about 0.01 mg/kg to about 10 mg/kg. 
     
     
         11 . The method of  claim 9 , wherein the MetAP2 inhibitor is administered at a dose of about 0.04 mg/kg to about 1.0 mg/kg. 
     
     
         12 . The method of  claim 1 , wherein the age-related neuromuscular disorder is sarcopenia. 
     
     
         13 . A method of treating sarcopenia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an irreversible MetAP2 inhibitor that covalently binds to MetAP2, wherein the therapeutically effective amount does not substantially modulate or suppress angiogenesis.